MZ-101

CAT: 0804-HY-157646-01Size: 5 mgDry Ice: NoHazardous: No
CAT#:0804-HY-157646-01Size:5 mg
Selected
AVAILABILITY: InStock
24/48H Stock Items & 2 to 6 Weeks non Stock Items.
Product image 1
1 / 1
Description
MZ-101 (GYS1-IN-2) is an orally active, potent and selective small-molecule glycogen synthase 1 (GYS1) inhibitor with with an IC50 value of 0.041 µM. MZ-101 reduces glycogen concentrations in cells and in mice. MZ-101 can used to study GYS1 -mediated Pompe disease and other glycogen storage diseases[1][2][3].
CAS Number
[2839908-40-4]
Product Name Alternative
GYS1-IN-2
UNSPSC
12352005
Target
Others
Type
Reference compound
Related Pathways
Others
Applications
Metabolism-sugar/lipid metabolism
Field of Research
Metabolic Disease
Assay Protocol
https://www.medchemexpress.com/mz-101.html
Purity
98.98
Solubility
DMSO : 100 mg/mL (ultrasonic; warming; heat to 60°C)
Smiles
O=C([C@H]1N(C[C@@H](C1)F)C(CC2=CN=NN2)=O)N[C@@H](C3=CC=CC=C3)C4=CC=C(C=C4)C(C)C
Molecular Formula
C25H28FN5O2
Molecular Weight
449.52
References & Citations
[1]David John Morgans, et al. Inhibitors of glycogen synthase 1 (gys1) and methods of use thereof. WO2022198196. 2022-09-22.|[2]Ullman JC, et al. Small-molecule inhibition of glycogen synthase 1 for the treatment of Pompe disease and other glycogen storage disorders. Sci Transl Med. 2024 Jan 17;16 (730) :eadf1691.|[3]Gaspar RC, et al. Small molecule inhibition of glycogen synthase I reduces muscle glycogen content and improves biomarkers in a mouse model of Pompe disease. Am J Physiol Endocrinol Metab. 2024 Oct 1;327 (4) :E524-E532.
Shipping Conditions
Room Temperature
Storage Conditions
-20°C, 3 years; 4°C, 2 years (Powder)
Scientific Category
Reference compound1
Clinical Information
No Development Reported

Popular Products